By Colin Kellaher
A second late-stage study of AbbVie’s antiwrinkle treatment Botox has met its key goals in platysma prominence, a part of the aging process that disrupts the neck, jawline and lower face.
AbbVie’s Allergan unit on Monday said the Phase 3 study of Botox in the treatment of moderate-to-severe platysma prominence met all primary and secondary endpoints, with study results consistent with findings from a prior Phase 3 study.
Allergan said it will include the study data as part of a U.S. Food and Drug Administration regulatory submission it expects to file near the end of the year, adding that an FDA green light would make Botox the first and only neurotoxin for platysma prominence, which results from contraction of a superficial, flat muscle in the lower face and neck.
Botox, which the FDA first approved in 1989 for a pair of rare eye muscle disorders, is currently FDA-approved for a raft of cosmetic and therapeutic indications. AbbVie posted combined Botox cosmetic and therapeutic revenue of more than $2.8 billion for the first half of 2023.
Write to Colin Kellaher at [email protected]
Read the full article here
